Radiotherapy outcomes and risk factors for young patients with head-and-neck squamous cell carcinomas: a matched-pair analysis

Abstract Background Head-and-neck squamous cell carcinomas (HNSCC) exhibit significant variations in incidence and outcomes across age groups. There is conflicting data on the oncological outcomes of younger HNSCC patients ≤ 45 years. This study analyzed clinical characteristics, treatment-related t...

Full description

Saved in:
Bibliographic Details
Main Authors: Jiadai Zou, Alexander Rühle, Henning Schäfer, Andreas Dietz, Gunnar Wichmann, Thomas Kuhnt, Anca-L. Grosu, Nils H. Nicolay
Format: Article
Language:English
Published: BMC 2025-04-01
Series:Radiation Oncology
Subjects:
Online Access:https://doi.org/10.1186/s13014-025-02631-w
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Head-and-neck squamous cell carcinomas (HNSCC) exhibit significant variations in incidence and outcomes across age groups. There is conflicting data on the oncological outcomes of younger HNSCC patients ≤ 45 years. This study analyzed clinical characteristics, treatment-related toxicities and survival rates of young HNSCC patients treated with (chemo)radiotherapy. Methods HNSCC patients ≤ 45 years treated with radiotherapy between 2009 and 2021 at two large cancer centers were analyzed and matched to a patient cohort > 45 years based on TNM and tumor localization. Overall (OS), progression-free (PFS) and metastasis-free (DMFS) survival and locoregional control (LRC) were compared and treatment-related toxicities were assessed. Results 99 patients were included in this analysis. Median OS of the young HNSCC cohort was 63 months. Daily alcohol consumption was identified as a key risk factor for reduced OS in the multivariate analysis. OS was similar in the young cohort compared to older patients, although the excess mortality risk compared to the sex- and age-matched general population amounted to 59-fold, while it was only 5.9-fold for patients ≥ 45 years. No significant differences were observed in PFS, LRC, or DMFS between age groups. Higher-grade chronic toxicities were moderate in young HNSCC patients. Conclusions Young HNSCC patients ≤ 45 years treated with (chemo)radiation have similar rates of oncological survival outcomes compared to older patients. While chronic toxicities from (chemo)radiation are low, further research is needed to explore the long-term quality-of-life.
ISSN:1748-717X